Newsletter Tool

Featured Story

Pfizer tightens DMD patient criteria after serious adverse events crop up in phase 3 gene therapy trial

By Annalee Armstrong

Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to participate in a phase 3 clinical trial for an experimental gene therapy after three serious adverse events were seen in ongoing studies.

In Humira kickbacks case, disgruntled AbbVie investors score class-action status

By Kevin Dunleavy

In federal court in Chicago, a judge has certified the class-action status of a securities fraud case against AbbVie. In the lawsuit, investors claim the company inflated its stock price by misleading the public about the effect of a kickback scheme on the value of Humira.

After $3.2B deal, Sanofi dumps Translate's mRNA COVID vaccine but hits the gas on switch to modified molecules

By Nick Paul Taylor

The ink on Sanofi’s $3.2 billion takeover of Translate Bio is barely dry, but the French big pharma is already tweaking its plans, dumping a COVID-19 vaccine prospect after seeing interim phase 1/2 data and accelerating its switch to modified mRNA.

KFF: Delta cases, hospitalizations lead to uptick in vaccinations

By Robert King

A new survey found that COVID-19 vaccinations among U.S. adults ticked up recently after major spikes in cases and hospitalizations due to the highly transmissible delta variant.

Vensana Capital redoubles medtech investment efforts with $325M 2nd fund

By Andrea Park

Vensana Capital II will enable the firm to scale up its investments in startups building medical devices, diagnostics and research tools, as well as digital health and other software platforms.

MIT cell-engineering spinout nets $30M for mass manufacturing platform

By Conor Hale

One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins. Kytopen aims to provide a fast and scalable method.

CVS Caremark takes aim at health inequities, starting with sickle cell, HIV

By Paige Minemyer

CVS Caremark is expanding its health equity efforts, setting goals that specifically target diseases that disproportionately impact patients of color, such as HIV and sickle cell disease.

Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts

By Angus Liu

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond Keytruda, but overlapping businesses could attract antitrust scrutiny, analysts say.

Fierce Biotech's 2021 Fierce 15

By Ben Adams

COVID-19 was inevitably the focus of Fierce 15 last year. This year, it’s pretty much more of the same as we see how the sector has and continues to navigate the pandemic while raising cash, running trials, hiring staff, keeping them safe, and making deals during an incredibly difficult 18 months.

PM Tracker